Simultaneous pharmacologic inhibition of PI3K and mTORC1 has demonstrated preclinical efficacy in ccRCC, however dose-limiting toxicity has hindered clinical use [49, 50]. Here, PIK3CA is linked to nonpapillary renal cell carcinoma.